Other equities research analysts have also issued research reports about the stock. William Blair reaffirmed a buy rating on shares of Axsome Therapeutics in a research report on Thursday, October 1st. Cantor Fitzgerald upped their price target on shares of Axsome Therapeutics from $131.00 to $161.00 and gave the company an overweight rating in a research report on Thursday, December 3rd. Bank of America started coverage on shares of Axsome Therapeutics in a report on Tuesday, September 29th. They issued an underperform rating and a $66.00 target price for the company. Morgan Stanley reduced their target price on shares of Axsome Therapeutics from $102.00 to $101.00 and set an overweight rating for the company in a report on Monday, November 9th. Finally, UBS Group reissued a positive rating on shares of Axsome Therapeutics in a report on Thursday, December 31st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and thirteen have issued a buy rating to the company’s stock. Axsome Therapeutics currently has a consensus rating of Buy and a consensus target price of $140.82.
Shares of NASDAQ:AXSM opened at $77.71 on Thursday. Axsome Therapeutics has a fifty-two week low of $35.44 and a fifty-two week high of $109.53. The business has a 50-day simple moving average of $78.74 and a two-hundred day simple moving average of $76.51. The company has a debt-to-equity ratio of 0.36, a quick ratio of 9.99 and a current ratio of 9.99. The firm has a market cap of $2.90 billion, a price-to-earnings ratio of -28.89 and a beta of 2.59.
Axsome Therapeutics (NASDAQ:AXSM) last released its quarterly earnings results on Tuesday, November 10th. The company reported ($0.58) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.57) by ($0.01). As a group, research analysts predict that Axsome Therapeutics will post -2.65 earnings per share for the current year.
Hedge funds have recently bought and sold shares of the business. NEXT Financial Group Inc bought a new position in Axsome Therapeutics in the 3rd quarter worth approximately $50,000. Lindbrook Capital LLC bought a new position in Axsome Therapeutics in the 3rd quarter worth approximately $50,000. Neo Ivy Capital Management bought a new position in Axsome Therapeutics in the 3rd quarter worth approximately $67,000. Clearstead Advisors LLC bought a new position in Axsome Therapeutics in the 3rd quarter worth approximately $71,000. Finally, Macquarie Group Ltd. bought a new position in Axsome Therapeutics in the 2nd quarter worth approximately $96,000. Institutional investors and hedge funds own 63.64% of the company’s stock.
Axsome Therapeutics Company Profile
Axsome Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05, which is in the phase III clinical trial for the treatment resistant depression and depressive disorders; and phase II/III clinical trials in agitation associated with Alzheimer’s disease, as well as completed phase II clinical trial for the treatment of smoking cessation.
Featured Article: Sell-Side Analysts
Receive News & Ratings for Axsome Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Axsome Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.